Brokerages Set Femasys Inc. (NASDAQ:FEMY) Target Price at $5.50

Shares of Femasys Inc. (NASDAQ:FEMY) have been assigned a consensus rating of “Moderate Buy” from the five ratings firms that are currently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation and four have given a buy recommendation to the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $5.50.

Several brokerages recently issued reports on FEMY. Wall Street Zen downgraded Femasys from a “hold” rating to a “sell” rating in a research note on Saturday. Lake Street Capital initiated coverage on shares of Femasys in a report on Tuesday, March 3rd. They set a “buy” rating and a $1.50 price objective for the company. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Femasys in a report on Thursday, January 22nd.

Femasys Trading Down 22.1%

Shares of Femasys stock opened at $0.38 on Friday. Femasys has a 1-year low of $0.31 and a 1-year high of $1.34. The company’s fifty day simple moving average is $0.54 and its 200-day simple moving average is $0.63. The company has a debt-to-equity ratio of 0.01, a current ratio of 1.16 and a quick ratio of 0.61. The stock has a market capitalization of $21.99 million, a PE ratio of -0.52 and a beta of -2.53.

Institutional Investors Weigh In On Femasys

A number of hedge funds have recently made changes to their positions in FEMY. Kovack Advisors Inc. purchased a new stake in shares of Femasys during the fourth quarter valued at $27,000. HRT Financial LP purchased a new stake in Femasys during the fourth quarter worth $30,000. Cetera Investment Advisers purchased a new position in Femasys in the fourth quarter valued at about $36,000. Osaic Holdings Inc. bought a new position in shares of Femasys during the 2nd quarter worth approximately $45,000. Finally, State Street Corp increased its position in shares of Femasys by 43.5% during the fourth quarter. State Street Corp now owns 80,869 shares of the company’s stock worth $47,000 after purchasing an additional 24,500 shares in the last quarter. 65.27% of the stock is currently owned by hedge funds and other institutional investors.

About Femasys

Femasys International, Inc is a medical device company focused on the research, development and commercialization of innovative technologies for interventional women’s health applications. The company’s core activities center on creating minimally invasive diagnostic and therapeutic products designed to address uterine cavity evaluation and treatment and to improve outcomes in gynecological care.

The company’s flagship product, the FemVue® hydrosonography system, is a single-use catheter-based device that enhances visualization of the uterine cavity through saline infusion sonography.